amiloride has been researched along with s 1033 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chang, CS; Chang, JG; Chang, WH; Chang, YS; Chen, YC; Chen, YT; Hsu, KC; Lee, CC; Lin, SY; Liu, TY; Wu, YC; Yang, JM | 1 |
1 review(s) available for amiloride and s 1033
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for amiloride and s 1033
| Article | Year |
|---|---|
Alternative splicing in human cancer cells is modulated by the amiloride derivative 3,5-diamino-6-chloro-N-(N-(2,6-dichlorobenzoyl)carbamimidoyl)pyrazine-2-carboxide.
Topics: Alternative Splicing; Amiloride; Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; G2 Phase; Gene Expression Regulation, Neoplastic; Genome, Human; Heterogeneous-Nuclear Ribonucleoproteins; Histones; Humans; Mice, Inbred BALB C; Mitosis; Models, Molecular; Molecular Targeted Therapy; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Pyrimidines; RNA, Messenger; Serine-Arginine Splicing Factors; Sorafenib; Xenograft Model Antitumor Assays | 2019 |